---
title: RUNX2 prompts triple negative breast cancer drug resistance through TGF-Î² pathway
  regulating breast cancer stem cells
date: '2024-01-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38219710/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240115170627&v=2.18.0
source: heidelberg[Affiliation]
description: Triple-negative breast cancer (TNBC) stands out as the most aggressive
  subtype within the spectrum of breast cancer. The current clinical guidelines propose
  treatment strategies involving cytotoxic agents like epirubicin or paclitaxel. However,
  the emergence of acquired resistance frequently precipitates secondary tumor recurrence
  or the spread of metastasis. In recent times, significant attention has been directed
  toward the transcription factor RUNX2, due to its pivotal role in ...
disable_comments: true
---
Triple-negative breast cancer (TNBC) stands out as the most aggressive subtype within the spectrum of breast cancer. The current clinical guidelines propose treatment strategies involving cytotoxic agents like epirubicin or paclitaxel. However, the emergence of acquired resistance frequently precipitates secondary tumor recurrence or the spread of metastasis. In recent times, significant attention has been directed toward the transcription factor RUNX2, due to its pivotal role in ...